Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer

Inclusion Criteria: * Subject is at least 18 years of age, able to understand the study procedures, and agrees to participate in the study by providing written informed consent * Subject has histologically or cytologically proven endometrial cancer * Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 * Adequate organ function allowing the patient to receive taxane-platinum combination therapy with or without immunotherapy according to clinical practice and opinion of treating physician * Naive to chemotherapy * Women of child-bearing potential must have a negative pregnancy test (urine). Female patients are considered of child-bearing potential following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Patients are considered to not be of child-bearing potential if they have a history of tubal ligation or hysterectomy or are post-menopausal with a minimum of 1 year without menses. Patients of child-bearing potential must agree to adequate birth control if conception is possible during the study and for 6 months after the last dose; in this case, patients must take a monthly pregnancy test for the duration of the study Exclusion Criteria: * They will experience emesis within the 24 hours before receipt of 1 course of chemotherapy * will be scheduled to radiation therapy to the abdomen or pel…